评估作为人类ClpP激动剂的二甲基胺化合物的结构活性关系和抗白血病活性
Ranran Zhang1, Pengyu Wang1, Bingyan Wei2
1School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou, 310024, China; State Key Laboratory of Drug Research, Centre for Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
一种新的化合物,ZG36,作为人体类蛋白酶P (ClpP) 的强有力的激动剂,有效降解急性髓性白血病 (AML) 细胞中的线粒体蛋白质. 这种向性降解导致白血病细胞死亡,并在临床前模型中抑制瘤生长.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 在瘤学瘤学.
背景情况:
- 人类ClpP蛋白酶调节线粒体蛋白质水解,是抗白血病疗法的标.
- 之前开发的ZG111,一种ClpP激动剂,通过降解呼吸链蛋白来显示对胰腺癌的疗效.
研究的目的:
- 为了研究ICG-001类型的结构-活性关系作为新型抗白血病药物.
- 评估ZG36化合物作为急性髓性白血病 (AML) 的潜在治疗药物的疗效.
主要方法:
- 研究了ICG-001类型的结构-活性关系.
- 在AML细胞系中通过ZG36评估ClpP的热稳定.
- 解决了ZG36/ClpP结构复合体的问题.
- 评估了ZG36对呼吸链复合体,线粒体DNA和细胞活力 in vitro 和 in vivo 的影响.
主要成果:
- 与ZG111相比,ZG36化合物在AML细胞中表现出增强的ClpP稳定,表明直接结合.
- ZG36/ClpP复杂结构阐明了它的作用机制.
- ZG36非选择性降解了呼吸链复合体,减少了线粒体DNA,并诱导了白血病细胞死亡.
- ZG36抑制了3D细胞生长,并抑制了AML异种移植瘤发生.
结论:
- 开发了一种新的类型的人类ClpP激动剂,其中ZG36作为化合物.
- ZG36有效地准线粒体功能,以获得抗白血病效应.
- ZG36显示出作为急性髓性白血病的新型治疗策略的潜力.
相关概念视频
Adrenergic Agonists: Chemistry and Structure-Activity Relationship
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of...
Structure-Activity Relationships and Drug Design
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
The direct-acting...
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
Antipsychotic Drugs: Typical and Atypical Agents


